Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments
- PMID: 40574020
- PMCID: PMC12195671
- DOI: 10.3390/pharmaceutics17060707
Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments
Abstract
The intestine is an important segment of the gastrointestinal tract, which is involved in complex processes that maintain the body's normal homeostasis. It hosts a vast, diverse, and dynamic microbial community called the gut microbiota, which develops from birth. It has been observed that the gut microbiota is involved in essential physiological processes, including the development of the central nervous system via the gut microbiota-brain axis. An alteration of the gut microbiota can lead to serious health problems, including defective neurodevelopment. Thus, this paper aims to highlight the most recent advances in studies that focus on the link between the gut microbiota and the evolution of neurodevelopmental diseases in children. Currently, studies show that the use of drugs that stimulate and restore the gut microbiota (e.g., probiotics and prebiotics) have the potential to alleviate some of the symptoms associated with conditions such as Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Tic Disorder, Tourette Syndrome, epilepsy, and Down Syndrome. In addition, due to the challenges associated with drug administration in children, as well as the widespread shortage of medications intended for pediatric use, researchers are working on the development of new delivery systems. Liposome-based systems or solid lipid nanoparticles have been safely used for drug delivery in various pediatric conditions, which may also indicate their potential for use in the administration of microbiota-modulating therapies.
Keywords: children neurodevelopmental disorders; gut microbiota; liposomal drug delivery systems; prebiotics; probiotics; solid lipid nanoparticles.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures





Similar articles
-
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2. Cochrane Database Syst Rev. 2022. PMID: 36126902 Free PMC article.
-
Radiation-induced injury and the gut microbiota: insights from a microbial perspective.Therap Adv Gastroenterol. 2025 Jun 16;18:17562848251347347. doi: 10.1177/17562848251347347. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 40535532 Free PMC article. Review.
-
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1. J Manag Care Pharm. 2012. PMID: 22784311 Free PMC article.
-
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x. Respir Res. 2024. PMID: 39709425 Free PMC article. Review.
-
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2. Cochrane Database Syst Rev. 2023. PMID: 37870148 Free PMC article.
Cited by
-
Dietary Principles, Interventions and Oxidative Stress in Psoriasis Management: Current and Future Perspectives.Medicina (Kaunas). 2025 Jul 18;61(7):1296. doi: 10.3390/medicina61071296. Medicina (Kaunas). 2025. PMID: 40731925 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources